nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—myocardium—dilated cardiomyopathy	0.0287	0.129	CbGeAlD
Lithium—GSK3B—myocardium—dilated cardiomyopathy	0.0281	0.126	CbGeAlD
Lithium—IMPA1—heart—dilated cardiomyopathy	0.0267	0.12	CbGeAlD
Lithium—GSK3A—cardiac ventricle—dilated cardiomyopathy	0.026	0.117	CbGeAlD
Lithium—GSK3A—myocardium—dilated cardiomyopathy	0.0245	0.11	CbGeAlD
Lithium—IMPA2—heart—dilated cardiomyopathy	0.02	0.09	CbGeAlD
Lithium—GSK3B—heart—dilated cardiomyopathy	0.0196	0.0883	CbGeAlD
Lithium—IMPA2—cardiac atrium—dilated cardiomyopathy	0.0171	0.077	CbGeAlD
Lithium—GSK3A—heart—dilated cardiomyopathy	0.0171	0.0768	CbGeAlD
Lithium—GSK3A—cardiac atrium—dilated cardiomyopathy	0.0146	0.0657	CbGeAlD
Lithium—Polydipsia—Furosemide—dilated cardiomyopathy	0.014	0.0614	CcSEcCtD
Lithium—Lethargy—Spironolactone—dilated cardiomyopathy	0.00592	0.0259	CcSEcCtD
Lithium—Blindness—Lisinopril—dilated cardiomyopathy	0.00589	0.0258	CcSEcCtD
Lithium—Ataxia—Spironolactone—dilated cardiomyopathy	0.00545	0.0239	CcSEcCtD
Lithium—Glycosuria—Furosemide—dilated cardiomyopathy	0.00536	0.0235	CcSEcCtD
Lithium—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00519	0.0227	CcSEcCtD
Lithium—Gastritis—Spironolactone—dilated cardiomyopathy	0.00513	0.0225	CcSEcCtD
Lithium—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00462	0.0202	CcSEcCtD
Lithium—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00447	0.0196	CcSEcCtD
Lithium—Memory impairment—Lisinopril—dilated cardiomyopathy	0.00415	0.0182	CcSEcCtD
Lithium—Urine output increased—Furosemide—dilated cardiomyopathy	0.00393	0.0172	CcSEcCtD
Lithium—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00368	0.0161	CcSEcCtD
Lithium—Polyuria—Furosemide—dilated cardiomyopathy	0.00359	0.0157	CcSEcCtD
Lithium—Swelling—Furosemide—dilated cardiomyopathy	0.00358	0.0157	CcSEcCtD
Lithium—Alopecia—Spironolactone—dilated cardiomyopathy	0.00354	0.0155	CcSEcCtD
Lithium—Oliguria—Lisinopril—dilated cardiomyopathy	0.00354	0.0155	CcSEcCtD
Lithium—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00347	0.0152	CcSEcCtD
Lithium—Thirst—Furosemide—dilated cardiomyopathy	0.00331	0.0145	CcSEcCtD
Lithium—Lethargy—Furosemide—dilated cardiomyopathy	0.00322	0.0141	CcSEcCtD
Lithium—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00317	0.0139	CcSEcCtD
Lithium—Discomfort—Spironolactone—dilated cardiomyopathy	0.00294	0.0129	CcSEcCtD
Lithium—Dehydration—Furosemide—dilated cardiomyopathy	0.00293	0.0128	CcSEcCtD
Lithium—Confusional state—Spironolactone—dilated cardiomyopathy	0.00287	0.0126	CcSEcCtD
Lithium—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00286	0.0125	CcSEcCtD
Lithium—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00278	0.0122	CcSEcCtD
Lithium—Somnolence—Spironolactone—dilated cardiomyopathy	0.00253	0.0111	CcSEcCtD
Lithium—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00246	0.0108	CcSEcCtD
Lithium—Drowsiness—Furosemide—dilated cardiomyopathy	0.00243	0.0106	CcSEcCtD
Lithium—GSK3B—Semaphorin interactions—ITGB1—dilated cardiomyopathy	0.00236	0.0043	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.00235	0.00428	CbGpPWpGaD
Lithium—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00235	0.0103	CcSEcCtD
Lithium—GSK3B—Wnt Signaling Pathway Netpath—RAC1—dilated cardiomyopathy	0.00233	0.00424	CbGpPWpGaD
Lithium—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00225	0.00986	CcSEcCtD
Lithium—Ataxia—Lisinopril—dilated cardiomyopathy	0.00223	0.00974	CcSEcCtD
Lithium—GSK3B—Cardiac Hypertrophic Response—RAC1—dilated cardiomyopathy	0.00222	0.00405	CbGpPWpGaD
Lithium—IMPA1—Metabolism—SDHA—dilated cardiomyopathy	0.0022	0.00401	CbGpPWpGaD
Lithium—Dehydration—Lisinopril—dilated cardiomyopathy	0.0022	0.00963	CcSEcCtD
Lithium—GRIA3—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00215	0.00392	CbGpPWpGaD
Lithium—GSK3B—Class I PI3K signaling events mediated by Akt—RAF1—dilated cardiomyopathy	0.00212	0.00386	CbGpPWpGaD
Lithium—Gastritis—Lisinopril—dilated cardiomyopathy	0.00209	0.00917	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—VCL—dilated cardiomyopathy	0.00204	0.00372	CbGpPWpGaD
Lithium—Tinnitus—Furosemide—dilated cardiomyopathy	0.00203	0.00891	CcSEcCtD
Lithium—GSK3B—CDC42 signaling events—RPS6KB1—dilated cardiomyopathy	0.00203	0.0037	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—RAC1—dilated cardiomyopathy	0.00197	0.00359	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.00196	0.00357	CbGpPWpGaD
Lithium—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00195	0.00853	CcSEcCtD
Lithium—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00195	0.00853	CcSEcCtD
Lithium—GRIA3—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00194	0.00354	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—GJA1—dilated cardiomyopathy	0.00193	0.00352	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00192	0.0035	CbGpPWpGaD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—RAC1—dilated cardiomyopathy	0.00191	0.00348	CbGpPWpGaD
Lithium—GSK3B—IL-5 Signaling Pathway—RAF1—dilated cardiomyopathy	0.0019	0.00347	CbGpPWpGaD
Lithium—GSK3B—Semaphorin interactions—RAC1—dilated cardiomyopathy	0.0019	0.00346	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway—RAC1—dilated cardiomyopathy	0.0019	0.00346	CbGpPWpGaD
Lithium—Dizziness—Spironolactone—dilated cardiomyopathy	0.00188	0.00825	CcSEcCtD
Lithium—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00188	0.00825	CcSEcCtD
Lithium—Flatulence—Furosemide—dilated cardiomyopathy	0.00187	0.00819	CcSEcCtD
Lithium—Weight increased—Lisinopril—dilated cardiomyopathy	0.00186	0.00815	CcSEcCtD
Lithium—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00186	0.00814	CcSEcCtD
Lithium—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00185	0.0081	CcSEcCtD
Lithium—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00185	0.00808	CcSEcCtD
Lithium—GSK3B—CDC42 signaling events—RAC1—dilated cardiomyopathy	0.00183	0.00334	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—RAF1—dilated cardiomyopathy	0.00183	0.00333	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00181	0.0033	CbGpPWpGaD
Lithium—Vomiting—Spironolactone—dilated cardiomyopathy	0.00181	0.00793	CcSEcCtD
Lithium—Rash—Spironolactone—dilated cardiomyopathy	0.0018	0.00786	CcSEcCtD
Lithium—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0018	0.00786	CcSEcCtD
Lithium—Vision blurred—Furosemide—dilated cardiomyopathy	0.00179	0.00784	CcSEcCtD
Lithium—Headache—Spironolactone—dilated cardiomyopathy	0.00179	0.00781	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.00178	0.00324	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.00178	0.00324	CbGpPWpGaD
Lithium—Agitation—Furosemide—dilated cardiomyopathy	0.00175	0.00764	CcSEcCtD
Lithium—GSK3B—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.00174	0.00316	CbGpPWpGaD
Lithium—Vertigo—Furosemide—dilated cardiomyopathy	0.00171	0.00747	CcSEcCtD
Lithium—GSK3B—Neural Crest Differentiation—ITGB1—dilated cardiomyopathy	0.0017	0.0031	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—FAS—dilated cardiomyopathy	0.0017	0.00309	CbGpPWpGaD
Lithium—Nausea—Spironolactone—dilated cardiomyopathy	0.00169	0.00741	CcSEcCtD
Lithium—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00167	0.0073	CcSEcCtD
Lithium—Hallucination—Lisinopril—dilated cardiomyopathy	0.00163	0.00713	CcSEcCtD
Lithium—IMPA1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.00162	0.00295	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.0016	0.00292	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—RAC1—dilated cardiomyopathy	0.00159	0.00289	CbGpPWpGaD
Lithium—Dry mouth—Furosemide—dilated cardiomyopathy	0.00158	0.00692	CcSEcCtD
Lithium—GSK3B—Signaling events mediated by Stem cell factor receptor (c-Kit)—RAF1—dilated cardiomyopathy	0.00157	0.00285	CbGpPWpGaD
Lithium—Confusional state—Furosemide—dilated cardiomyopathy	0.00156	0.00684	CcSEcCtD
Lithium—GSK3A—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.00156	0.00284	CbGpPWpGaD
Lithium—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00153	0.00668	CcSEcCtD
Lithium—Shock—Furosemide—dilated cardiomyopathy	0.00153	0.00668	CcSEcCtD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—AGT—dilated cardiomyopathy	0.00151	0.00276	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—RAC1—dilated cardiomyopathy	0.00151	0.00276	CbGpPWpGaD
Lithium—Anorexia—Furosemide—dilated cardiomyopathy	0.00148	0.00647	CcSEcCtD
Lithium—GSK3B—Cardiac Hypertrophic Response—RAF1—dilated cardiomyopathy	0.00147	0.00269	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—SOD2—dilated cardiomyopathy	0.00147	0.00268	CbGpPWpGaD
Lithium—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00146	0.0064	CcSEcCtD
Lithium—Hypotension—Furosemide—dilated cardiomyopathy	0.00145	0.00634	CcSEcCtD
Lithium—Alopecia—Lisinopril—dilated cardiomyopathy	0.00145	0.00633	CcSEcCtD
Lithium—GSK3A—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.00142	0.00258	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.00142	0.00258	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—RAC1—dilated cardiomyopathy	0.00141	0.00257	CbGpPWpGaD
Lithium—Flatulence—Lisinopril—dilated cardiomyopathy	0.0014	0.00615	CcSEcCtD
Lithium—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0014	0.00611	CcSEcCtD
Lithium—Somnolence—Furosemide—dilated cardiomyopathy	0.00138	0.00603	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—FASLG—dilated cardiomyopathy	0.00136	0.00248	CbGpPWpGaD
Lithium—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00135	0.0059	CcSEcCtD
Lithium—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00134	0.00588	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.00134	0.00244	CbGpPWpGaD
Lithium—Fatigue—Furosemide—dilated cardiomyopathy	0.00134	0.00585	CcSEcCtD
Lithium—Tremor—Lisinopril—dilated cardiomyopathy	0.00134	0.00585	CcSEcCtD
Lithium—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00132	0.0024	CbGpPWpGaD
Lithium—Angioedema—Lisinopril—dilated cardiomyopathy	0.0013	0.0057	CcSEcCtD
Lithium—GRIA3—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.00129	0.00235	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—RAC1—dilated cardiomyopathy	0.00129	0.00234	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—RAC1—dilated cardiomyopathy	0.00128	0.00233	CbGpPWpGaD
Lithium—Vertigo—Lisinopril—dilated cardiomyopathy	0.00128	0.00561	CcSEcCtD
Lithium—Syncope—Lisinopril—dilated cardiomyopathy	0.00128	0.00559	CcSEcCtD
Lithium—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00128	0.00559	CcSEcCtD
Lithium—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00127	0.00555	CcSEcCtD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.00127	0.00231	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—RAC1—dilated cardiomyopathy	0.00126	0.00229	CbGpPWpGaD
Lithium—GSK3B—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—dilated cardiomyopathy	0.00125	0.00229	CbGpPWpGaD
Lithium—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00125	0.00548	CcSEcCtD
Lithium—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00123	0.00536	CcSEcCtD
Lithium—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00123	0.00536	CcSEcCtD
Lithium—GSK3B—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.00122	0.00221	CbGpPWpGaD
Lithium—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00121	0.00531	CcSEcCtD
Lithium—Discomfort—Lisinopril—dilated cardiomyopathy	0.0012	0.00525	CcSEcCtD
Lithium—GSK3B—TWEAK Signaling Pathway—TNF—dilated cardiomyopathy	0.0012	0.00218	CbGpPWpGaD
Lithium—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00119	0.00519	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.00118	0.00215	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—RAC1—dilated cardiomyopathy	0.00118	0.00215	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.00118	0.00215	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00118	0.00214	CbGpPWpGaD
Lithium—Confusional state—Lisinopril—dilated cardiomyopathy	0.00117	0.00513	CcSEcCtD
Lithium—Oedema—Lisinopril—dilated cardiomyopathy	0.00116	0.00509	CcSEcCtD
Lithium—GSK3B—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.00115	0.0021	CbGpPWpGaD
Lithium—Shock—Lisinopril—dilated cardiomyopathy	0.00114	0.00501	CcSEcCtD
Lithium—GSK3B—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00114	0.00208	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00113	0.00207	CbGpPWpGaD
Lithium—Asthenia—Furosemide—dilated cardiomyopathy	0.00111	0.00487	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00111	0.00202	CbGpPWpGaD
Lithium—Anorexia—Lisinopril—dilated cardiomyopathy	0.00111	0.00485	CcSEcCtD
Lithium—Hypotension—Lisinopril—dilated cardiomyopathy	0.00109	0.00476	CcSEcCtD
Lithium—GSK3B—Axon guidance—PSEN2—dilated cardiomyopathy	0.00107	0.00195	CbGpPWpGaD
Lithium—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00106	0.00464	CcSEcCtD
Lithium—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00106	0.00464	CcSEcCtD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.00105	0.00191	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.00105	0.00191	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.00105	0.00191	CbGpPWpGaD
Lithium—Somnolence—Lisinopril—dilated cardiomyopathy	0.00103	0.00453	CcSEcCtD
Lithium—GSK3B—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00103	0.00188	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—ITGB1—dilated cardiomyopathy	0.00103	0.00187	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—EGFR—dilated cardiomyopathy	0.00103	0.00187	CbGpPWpGaD
Lithium—Dizziness—Furosemide—dilated cardiomyopathy	0.00103	0.00449	CcSEcCtD
Lithium—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00102	0.00448	CcSEcCtD
Lithium—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00101	0.00443	CcSEcCtD
Lithium—Fatigue—Lisinopril—dilated cardiomyopathy	0.001	0.00439	CcSEcCtD
Lithium—GRIA3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000991	0.00181	CbGpPWpGaD
Lithium—Vomiting—Furosemide—dilated cardiomyopathy	0.000986	0.00431	CcSEcCtD
Lithium—Rash—Furosemide—dilated cardiomyopathy	0.000977	0.00428	CcSEcCtD
Lithium—GSK3B—Corticotropin-releasing hormone—RAF1—dilated cardiomyopathy	0.000977	0.00178	CbGpPWpGaD
Lithium—Dermatitis—Furosemide—dilated cardiomyopathy	0.000977	0.00427	CcSEcCtD
Lithium—Headache—Furosemide—dilated cardiomyopathy	0.000971	0.00425	CcSEcCtD
Lithium—GSK3B—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.000963	0.00175	CbGpPWpGaD
Lithium—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000959	0.0042	CcSEcCtD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000957	0.00174	CbGpPWpGaD
Lithium—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000951	0.00416	CcSEcCtD
Lithium—GSK3B—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000947	0.00172	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.00094	0.00171	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000937	0.00171	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—RAC1—dilated cardiomyopathy	0.000928	0.00169	CbGpPWpGaD
Lithium—Nausea—Furosemide—dilated cardiomyopathy	0.000921	0.00403	CcSEcCtD
Lithium—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00092	0.00403	CcSEcCtD
Lithium—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00092	0.00403	CcSEcCtD
Lithium—GSK3A—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000899	0.00164	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000896	0.00163	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000885	0.00161	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000879	0.0016	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000873	0.00159	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000873	0.00159	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000862	0.00157	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000849	0.00155	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000845	0.00154	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000842	0.00153	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000841	0.00153	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000837	0.00152	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000835	0.00152	CbGpPWpGaD
Lithium—Asthenia—Lisinopril—dilated cardiomyopathy	0.000835	0.00365	CcSEcCtD
Lithium—GSK3A—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000833	0.00152	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—RAC1—dilated cardiomyopathy	0.000825	0.0015	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000816	0.00149	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000805	0.00147	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000804	0.00147	CbGpPWpGaD
Lithium—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000796	0.00348	CcSEcCtD
Lithium—GSK3A—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000783	0.00143	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000783	0.00143	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000783	0.00143	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000776	0.00141	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.00077	0.0014	CbGpPWpGaD
Lithium—Dizziness—Lisinopril—dilated cardiomyopathy	0.000769	0.00337	CcSEcCtD
Lithium—GSK3A—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000766	0.0014	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000764	0.00139	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—RAF1—dilated cardiomyopathy	0.00076	0.00138	CbGpPWpGaD
Lithium—Vomiting—Lisinopril—dilated cardiomyopathy	0.00074	0.00324	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000737	0.00134	CbGpPWpGaD
Lithium—Rash—Lisinopril—dilated cardiomyopathy	0.000733	0.00321	CcSEcCtD
Lithium—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000733	0.00321	CcSEcCtD
Lithium—Headache—Lisinopril—dilated cardiomyopathy	0.000729	0.00319	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000724	0.00132	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TNF—dilated cardiomyopathy	0.000721	0.00131	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000707	0.00129	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.0007	0.00128	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000694	0.00126	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000694	0.00126	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000691	0.00126	CbGpPWpGaD
Lithium—Nausea—Lisinopril—dilated cardiomyopathy	0.000691	0.00302	CcSEcCtD
Lithium—GSK3B—Androgen receptor signaling pathway—EGFR—dilated cardiomyopathy	0.000688	0.00125	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000686	0.00125	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000683	0.00124	CbGpPWpGaD
Lithium—IMPA2—Metabolism—GPX1—dilated cardiomyopathy	0.000671	0.00122	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ITGB1—dilated cardiomyopathy	0.00067	0.00122	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000664	0.00121	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000654	0.00119	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CD36—dilated cardiomyopathy	0.000654	0.00119	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000644	0.00117	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000637	0.00116	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000628	0.00114	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000625	0.00114	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000622	0.00113	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000621	0.00113	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000618	0.00113	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000617	0.00112	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000617	0.00112	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000615	0.00112	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.00061	0.00111	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000607	0.00111	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000605	0.0011	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000603	0.0011	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GPX1—dilated cardiomyopathy	0.000598	0.00109	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000595	0.00108	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AGT—dilated cardiomyopathy	0.000589	0.00107	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CD36—dilated cardiomyopathy	0.000583	0.00106	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.00058	0.00106	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000579	0.00105	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000579	0.00105	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000579	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000577	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000574	0.00105	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000574	0.00105	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000571	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000569	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000566	0.00103	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000563	0.00103	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000548	0.000999	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—RAC1—dilated cardiomyopathy	0.000548	0.000998	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—RAF1—dilated cardiomyopathy	0.000547	0.000996	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—RAC1—dilated cardiomyopathy	0.000538	0.00098	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000537	0.000979	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000537	0.000979	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000537	0.000979	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000534	0.000972	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000532	0.00097	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000528	0.000961	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000525	0.000957	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AGT—dilated cardiomyopathy	0.000525	0.000956	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000513	0.000934	CbGpPWpGaD
Lithium—GSK3A—Disease—NPPA—dilated cardiomyopathy	0.000507	0.000923	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000506	0.000921	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—EGFR—dilated cardiomyopathy	0.000497	0.000906	CbGpPWpGaD
Lithium—GSK3A—Disease—PSEN2—dilated cardiomyopathy	0.000491	0.000894	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD36—dilated cardiomyopathy	0.000487	0.000887	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000481	0.000877	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000478	0.00087	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000476	0.000867	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000476	0.000867	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000468	0.000852	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—RAC1—dilated cardiomyopathy	0.000459	0.000836	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000456	0.00083	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000448	0.000817	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000441	0.000803	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000428	0.00078	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000426	0.000776	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000424	0.000772	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000422	0.000769	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000416	0.000758	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CD36—dilated cardiomyopathy	0.000408	0.000742	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000405	0.000738	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000397	0.000723	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000397	0.000723	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000397	0.000723	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000394	0.000718	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000393	0.000717	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.00039	0.00071	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000388	0.000707	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RAC1—dilated cardiomyopathy	0.000384	0.0007	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000383	0.000698	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—dilated cardiomyopathy	0.000375	0.000683	CbGpPWpGaD
Lithium—GSK3B—Disease—NPPA—dilated cardiomyopathy	0.000375	0.000682	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—dilated cardiomyopathy	0.000367	0.000669	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000366	0.000667	CbGpPWpGaD
Lithium—GSK3B—Disease—PSEN2—dilated cardiomyopathy	0.000363	0.000661	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD36—dilated cardiomyopathy	0.00036	0.000656	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—RAF1—dilated cardiomyopathy	0.000357	0.00065	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000352	0.00064	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000346	0.00063	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000344	0.000626	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RAC1—dilated cardiomyopathy	0.000339	0.000618	CbGpPWpGaD
Lithium—GSK3A—Immune System—ITGB1—dilated cardiomyopathy	0.000333	0.000606	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000326	0.000593	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000305	0.000556	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000305	0.000556	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—RAF1—dilated cardiomyopathy	0.000304	0.000554	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000292	0.000532	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000284	0.000517	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD36—dilated cardiomyopathy	0.000284	0.000517	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000275	0.000501	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—dilated cardiomyopathy	0.00027	0.000493	CbGpPWpGaD
Lithium—GSK3A—Immune System—RAC1—dilated cardiomyopathy	0.000267	0.000487	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RAF1—dilated cardiomyopathy	0.000255	0.000464	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000254	0.000463	CbGpPWpGaD
Lithium—GSK3A—Disease—RAC1—dilated cardiomyopathy	0.000247	0.00045	CbGpPWpGaD
Lithium—GSK3B—Immune System—ITGB1—dilated cardiomyopathy	0.000246	0.000448	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—dilated cardiomyopathy	0.000245	0.000446	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000235	0.000428	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000226	0.000411	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000226	0.000411	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RAF1—dilated cardiomyopathy	0.000225	0.00041	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000223	0.000406	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000216	0.000393	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.00021	0.000382	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD36—dilated cardiomyopathy	0.00021	0.000382	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—dilated cardiomyopathy	0.000209	0.00038	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000203	0.00037	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—dilated cardiomyopathy	0.0002	0.000365	CbGpPWpGaD
Lithium—GSK3B—Immune System—RAC1—dilated cardiomyopathy	0.000198	0.00036	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000191	0.000349	CbGpPWpGaD
Lithium—GSK3B—Disease—RAC1—dilated cardiomyopathy	0.000182	0.000332	CbGpPWpGaD
Lithium—GSK3A—Immune System—RAF1—dilated cardiomyopathy	0.000177	0.000323	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—dilated cardiomyopathy	0.000175	0.000318	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000173	0.000316	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000173	0.000315	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—dilated cardiomyopathy	0.000166	0.000303	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000165	0.000301	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000165	0.0003	CbGpPWpGaD
Lithium—GSK3A—Disease—RAF1—dilated cardiomyopathy	0.000164	0.000298	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—dilated cardiomyopathy	0.000154	0.000281	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—dilated cardiomyopathy	0.000148	0.00027	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000141	0.000258	CbGpPWpGaD
Lithium—GSK3B—Immune System—RAF1—dilated cardiomyopathy	0.000131	0.000239	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000128	0.000233	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGT—dilated cardiomyopathy	0.000122	0.000222	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—dilated cardiomyopathy	0.000122	0.000221	CbGpPWpGaD
Lithium—GSK3B—Disease—RAF1—dilated cardiomyopathy	0.000121	0.00022	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000115	0.000209	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—dilated cardiomyopathy	0.000112	0.000204	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—dilated cardiomyopathy	8.98e-05	0.000164	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RAF1—dilated cardiomyopathy	8.47e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—dilated cardiomyopathy	8.3e-05	0.000151	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—dilated cardiomyopathy	7.86e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—dilated cardiomyopathy	5.81e-05	0.000106	CbGpPWpGaD
